Goldman Sachs Upgrades Chemours On Improving End Markets
Chemours Co.’s (NYSE: CC) near-term prospects are now brighter, driven by TiO2 cycle improvement and growth in the Fluoroproducts business due to a cyclical recovery and secular trends, according to Goldman Sachs.